Vertex Pharmaceuticals Inc (VRTX)

Vertex Pharmaceuticals has underperformed the broader market over the past 12 months, but the biotech company shows signs of a potential rebound. With its core cystic fibrosis franchise continuing to drive growth and several promising pipeline candidates approaching regulatory approval—including povetacicept for kidney disease, inaxaplin for APOL-1-mediated kidney disease, and zimislecel for Type 1 diabetes—the company's long-term prospects appear strong, making it a potential buying opportunity.

The Motley Fool•Prosper Junior Bakiny

Mar 25

Avaí Bio announced a critical milestone in creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, an anti-aging protein that declines by 50% after age 40. The company is partnering with Austrianova to use Cell-in-a-Box encapsulation technology for its Klothonova anti-aging and Insulinova diabetes programs. This development occurs as the cell and gene therapy market expands rapidly, with the sector forecast to grow from $10.4 billion to over $45 billion by 2035.

Benzinga•Equity-Insider.Com

Mar 24

CRISPR Therapeutics stock has declined 9% this year following a $585.2 million convertible notes offering. While the company has an approved gene-editing therapy (Casgevy) and strong financial reserves of $1.8 billion, it remains deeply unprofitable with a net loss of $581.6 million and minimal revenue of $3.5 million. The analyst suggests it may be worth considering as a mid-cap growth stock with potential upside, though not a bargain due to inherent risks.

The Motley Fool•David Jagielski, Cpa

Mar 23

The article recommends three pharmaceutical stocks as attractive long-term holdings: Eli Lilly, which dominates the growing chronic weight management market with its blockbuster drug tirzepatide; Vertex Pharmaceuticals, which maintains a monopoly in cystic fibrosis treatments while expanding into other therapeutic areas; and Pfizer, which despite recent underperformance, offers undervalued shares, a strong pipeline, and an attractive 6.3% dividend yield.

The Motley Fool•Prosper Junior Bakiny

Mar 20

Eli Lilly and Vertex Pharmaceuticals are both prominent drugmakers with strong track records, but Eli Lilly emerges as the better growth stock choice. Eli Lilly leads the rapidly growing weight-loss market with Zepbound and has a strong pipeline including orforglipron and retatrutide, plus newer approvals in Alzheimer's and eczema treatments. Vertex Pharmaceuticals has a solid cystic fibrosis franchise and is expanding into sickle cell disease, acute pain, and kidney disease treatments. However, Eli Lilly generates higher revenue and net income with faster growth, and both companies have similar valuations, giving Eli Lilly the edge.

The Motley Fool•Prosper Junior Bakiny

Mar 19

The 2026 UNCF 'A Mind Is...' New England Gala raised a record-breaking $800,000 to support historically Black colleges and universities and provide scholarships to students. The event honored Demond Martin, Governor Charlie Baker, and Pamela Everhart for their contributions to educational equity and community development.

GlobeNewswire Inc.•Uncf

Mar 19

Vertex Pharmaceuticals, a biotech leader in cystic fibrosis treatment, is expanding into new therapeutic areas with recent approvals for Casgevy (blood disorders) and Journavx (non-opioid pain). The company's kidney disease candidate povetacicept is expected to be submitted for regulatory review by month-end. With $12 billion in annual sales and non-CF drugs projected to generate $500 million this year, analysts suggest the stock trading at $480 could reach $600 (25% gain) if new drug revenues perform strongly and pipeline advancements continue.

The Motley Fool•Adria Cimino

Mar 16

U.S. stocks rallied Tuesday as crude oil plummeted 10% to $85/barrel following President Trump's signals that the Iran conflict may be ending soon and his commitment to keep the Strait of Hormuz safe. The S&P 500 rose 0.3%, Dow gained 0.4%, and Nasdaq 100 advanced 0.5%, while the VIX dropped 9.3% signaling reduced market fear.

Benzinga•Piero Cingari

Mar 10

Vertex Pharmaceuticals shares surged 6.32% in premarket trading after announcing positive Phase 3 RAINIER trial results for its kidney drug povetacicept. The trial met its primary objective with a 52% reduction in urine protein and 49.8% reduction versus placebo. An analyst upgraded the probability of success to 90% ahead of expected FDA approval by year-end.

Benzinga•Vandana Singh

Mar 10

The article recommends two biotech companies as strong portfolio additions in 2026. Regeneron Pharmaceuticals is highlighted for its blockbuster drugs Dupixent and Eylea HD showing strong sales growth, along with a rich pipeline in multiple therapeutic areas, trading at a reasonable 17x forward earnings. Vertex Pharmaceuticals is praised as the leading cystic fibrosis treatment player with strong intellectual property protection and recent expansion into gene-editing and pain management, trading at 24x forward earnings.

The Motley Fool•Adria Cimino

Mar 5